Company news
Mauna Kea Technologies Sa Class O (EURONEXT:ALMKT) news
Every Mauna Kea Technologies Sa Class O press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Cl...
August 26, 2026
Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital
August 7, 2026
Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination w...
July 28, 2026
Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth
July 21, 2026
Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity
July 16, 2026
Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth
July 15, 2026
Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026
June 4, 2026
Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio®— Assessed Therapeutic Targ...
June 3, 2026
Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial I...
May 20, 2026
Mauna Kea Technologies Announces Nomination of 3 New Directors
May 18, 2026
Mauna Kea Technologies : AGM 2026 – Candidate Profiles
May 11, 2026
Mauna Kea Technologies : AGM 2026 – Resolutions
May 11, 2026
Mauna Kea Technologies : AGM 2026 – Notice of Meeting for Registered Shareholders
May 11, 2026
Mauna Kea Technologies : AGM 2026 – Board’s Report on Resolutions
May 11, 2026
Mauna Kea Technologies : 2025 Annual Financial Report (free translation)
May 11, 2026
Mauna Kea Technologies: Publication of the 2025 Annual Financial Report
April 30, 2026
Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026
April 28, 2026
Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Trans...
April 22, 2026
Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth
April 15, 2026
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
April 8, 2026
Mauna Kea Technologies Updates Its Financial Calendar
March 17, 2026
Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plena...
March 11, 2026
Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom
February 23, 2026
Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes
February 10, 2026
Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States
February 4, 2026
Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities
January 26, 2026
Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums
January 21, 2026
Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S.
January 15, 2026
Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreat...
December 3, 2025
Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform
November 20, 2025
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise
November 14, 2025
Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise
November 13, 2025
Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase
October 21, 2025
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates
October 13, 2025
Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan
October 8, 2025
Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring
October 6, 2025
Mauna Kea Technologies Announces 2025 Half-Year Results
October 1, 2025
Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan
September 22, 2025
Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion
September 18, 2025
Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround
September 12, 2025
Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Comme...
September 8, 2025
Mauna Kea Technologies Reports First Half 2025 Revenue
July 28, 2025
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
July 24, 2025
Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the...
July 21, 2025
Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio
July 15, 2025
Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure
July 10, 2025
Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure
July 10, 2025
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
June 5, 2025
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
June 2, 2025
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
May 21, 2025